Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

Phase 4 Completed 117 enrolled University of Maryland, Baltimore Ortho-McNeil Neurologics, Inc. · collab Stanley Medical Research Institute · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.

Timeline

Start: 2002-05
Primary completion: 2006-12
Completion: 2006-12

Publications

Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry. 2008 Jan;165(1):82-9. doi: 10.1176/appi.ajp.2007.07050724. Epub 2007 Nov 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Galantamine	Small molecule	24 mg	Oral

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

Summary

Timeline

Publications

Drugs

Indications